WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize. - ppt download
CRNM - "Clinically Relevant Non-Major Bleeding" by AcronymsAndSlang.com
New strategies for effective treatment of vitamin K antagonist‐associated bleeding - ScienceDirect
Direct Oral Anticoagulants: A User's Guide | Consultant360
Abstract 12434: Long-Term Clinical Outcomes After Major versus Minor Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry | Circulation
Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials | Scientific Reports
Evaluation of Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in the Oncology Population Jessica Hedvat, PharmD PGY-1 Pharmacy. - ppt download
Safety outcome of major bleeding or clinically relevant non-major bleeding. | Download Scientific Diagram
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry | Journal of Thrombosis and Thrombolysis
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series - The Lancet Haematology
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial | Haematologica
MASTER DAPT | Terumo Interventional Systems
new oral anticoagulants | PPT
Anthos' Blood Thinner Abelacimab Outperforms Rivals in Safety by 67% in AF Patients
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Practical Management of Anticoagulation in Patients With Atrial Fibrillation | Journal of the American College of Cardiology
Assessing Bleed Severity and Managing Major and Non-Major Bleeds | Download Scientific Diagram
Rivaroxaban for cancer-associated venous thromboembolism - Bo Liang, Yi Liang, Li-Zhi Zhao, Yu-Xiu Zhao, Ning Gu, 2021
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67%
Clinically relevant non-major bleeding and intra-cranial haemorrhage in... | Download Scientific Diagram
Non-major bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention with atrial fibrillation: a systematic review and network meta-analysis | European Journal of Clinical Pharmacology
